Gilead to buy cancer drugmaker Immunomedics for $21 billion

    0
    120
    Gilead to buy cancer drugmaker Immunomedics for $21 billion

    (Reuters) – Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining acce…
    Read More

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here